Skip to main content
Figure 4 | Molecular Medicine

Figure 4

From: A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate Aβ Peptides

Figure 4

AβpE3-8:CRM197 antiserum immunoreactivity in AD brains. (A) WB analysis of recombinant Aβ 1–42, AβpE3-42 and AβpE11-42 using 6E10 (anti-Aβ1–16) and 4G8 (anti-Aβ 17–24) antibodies, or AβpE3-8:CRM197 antiserum showing the specificity of the AβpE3-8: CRM197 antiserum toward AβpE3-42. (B) Western Blot analysis of human brain homogenates obtained from normal or AD cases (Braak stage V-VI, see Table 1) using PHF1 (anti-phospho-Ser396/404 tau), actin and 6E10 antibodies or AβpE3-8:CRM197 antiserum. (C) Immunohistochemistry of serial brain sections from an AD case stained with 6E10 antibody or AβpE3-8:CRM197 antiserum.

Back to article page

Molecular Medicine

ISSN: 1528-3658